Overview

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.
Phase:
Phase 2
Details
Lead Sponsor:
Sundeep Khosla, M.D.
Treatments:
Dasatinib
Quercetin